Non-Hodgkin's Lymphoma - Is there room to emulate Rituxan's success?

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2007-12-19

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy and is comprised of around 30 different disease subtypes. Each of these present with a distinct set histological, genetic and clinical characteristics. Treatment options in NHL include chemotherapy, targeted therapies, stem cell transplantation and radiotherapy.


Scope

  • NHL background and epidemiology, including forecast incidence of the major subtypes in the seven major markets
  • Treatment of NHL by subtype and line of therapy, including major treatment controversies and areas of unmet need
  • Examination of pipeline activity including profiles of late-phase pipeline drugs
  • Stakeholder opinions based on qualitative interviews with opinion leaders from the US and Europe


    • Report Highlights Rituxan-based regimens constitute the mainstay of first-line treatment options in several NHL subtypes. Uptake of Rituxan in the maintenance setting for follicular lymphoma (FL) has allowed the drug to achieve further market penetration.

    There is a lack of consensus over the treatment of relapsed and refractory disease in most NHL subtypes. Refractory patients are poorly served by currently available treatment options. Other unmet needs include detection of patients with aggressive lymphoma at high risk of relapse and an efficacious maintenance therapy for these patients.

    The NHL late-phase pipeline is relatively active, with 10 Phase IIII drugs and 46 Phase II drugs. Monoclonal antibodies are among those agents that continue to demonstrate promising signs of clinical and commercial potential. However, Rituxan's status as market leader is unlikely to be challenged within the next 510 years.


    Reasons to Purchase

  • Understand current epidemiological trends in non-Hodgkin's lymphoma and ongoing treatment options
  • Identify limitations of therapy currently available to non-Hodgkin's lymphoma patients and the potential of future therapy
  • Identify the key products in late-phase development for NHL. Consider, assess and react to opportunities and risks influencing their future potential

    • Table of Contents

    Other users found this report page using the following search terms: lymphoma lymphoma non hodgkins rituxan nhl success treatment nonhodgkins dlbcl line

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.